EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Clinical Outcomes of Abrocitinib in Prurigo Spectrum Disorders: A Case Series

Uma Chakravadhanula, Manjula Nagarajan, Shilpa Bhat

Cureus · 23.04.2026

DOI: 10.7759/cureus.107619 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cureus, erschienen am 23.04.2026. Verfasst von Uma Chakravadhanula und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology, Institute of Diabetes, Endocrinology, and Adiposity (IDEA) Clinics, Hyderabad, IND. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

abrocitinibitchingjak inhibitorprurigo nodularisprurigo simplex

Autor:innen und Institutionen

  • Dermatology, Institute of Diabetes, Endocrinology, and Adiposity (IDEA) Clinics, Hyderabad, IND.
  • Dermatology, SAAR Clinic, Erode, IND.
  • Dermatology, Subodha Skin, Hair, and Cosmetic Clinic, Bangalore, IND.

Zitieren

APA

Chakravadhanula, U., Nagarajan, M., & Bhat, S. (2026). Clinical Outcomes of Abrocitinib in Prurigo Spectrum Disorders: A Case Series. Cureus. https://doi.org/10.7759/cureus.107619

Vancouver

Chakravadhanula U, Nagarajan M, Bhat S. Clinical Outcomes of Abrocitinib in Prurigo Spectrum Disorders: A Case Series. Cureus. 2026. doi:10.7759/cureus.107619

BibTeX
@article{Chakravadhanula2026,
  author = {Chakravadhanula, Uma and Nagarajan, Manjula and Bhat, Shilpa},
  title = {Clinical Outcomes of Abrocitinib in Prurigo Spectrum Disorders: A Case Series},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.107619}
}
Kostenlos starten →